JP2020529987A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529987A5 JP2020529987A5 JP2020505224A JP2020505224A JP2020529987A5 JP 2020529987 A5 JP2020529987 A5 JP 2020529987A5 JP 2020505224 A JP2020505224 A JP 2020505224A JP 2020505224 A JP2020505224 A JP 2020505224A JP 2020529987 A5 JP2020529987 A5 JP 2020529987A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutically acceptable
- acceptable salt
- alkyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 84
- 150000003839 salts Chemical class 0.000 claims description 78
- 229910052739 hydrogen Inorganic materials 0.000 claims description 50
- 239000013078 crystal Substances 0.000 claims description 45
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 claims description 28
- 206010009887 colitis Diseases 0.000 claims description 25
- 229910052757 nitrogen Inorganic materials 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 241000124008 Mammalia Species 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 16
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 16
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 14
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 12
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 208000015943 Coeliac disease Diseases 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 201000004624 Dermatitis Diseases 0.000 claims description 6
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 125000002950 monocyclic group Chemical group 0.000 claims description 6
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 6
- 201000005962 mycosis fungoides Diseases 0.000 claims description 6
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 6
- 208000009137 Behcet syndrome Diseases 0.000 claims description 5
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 5
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 206010058838 Enterocolitis infectious Diseases 0.000 claims description 5
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims description 5
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 5
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 5
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims description 5
- 208000009326 ileitis Diseases 0.000 claims description 5
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 5
- 208000027139 infectious colitis Diseases 0.000 claims description 5
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 4
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- QPEJAHMNOVMSOZ-UHFFFAOYSA-N 2-azaspiro[3.3]heptane Chemical compound C1CCC21CNC2 QPEJAHMNOVMSOZ-UHFFFAOYSA-N 0.000 claims description 2
- DGGKXQQCVPAUEA-UHFFFAOYSA-N 8-azabicyclo[3.2.1]octane Chemical compound C1CCC2CCC1N2 DGGKXQQCVPAUEA-UHFFFAOYSA-N 0.000 claims description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims 2
- 125000004585 polycyclic heterocycle group Chemical group 0.000 claims 2
- 238000011257 definitive treatment Methods 0.000 claims 1
- -1 1,2 - difluoro ethyl Chemical group 0.000 description 33
- 239000000243 solution Substances 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 3
- 206010067472 Organising pneumonia Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 201000009805 cryptogenic organizing pneumonia Diseases 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- 230000000414 obstructive effect Effects 0.000 description 3
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- KKGNNTRMDRNYDJ-SMMXGFFBSA-N (E)-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enoic acid Chemical compound CN1CCC[C@@H]1\C=C\C(O)=O KKGNNTRMDRNYDJ-SMMXGFFBSA-N 0.000 description 2
- 0 *CC(CCCCCCN*I)IC(c1c(*)[n]nc1)=*C(c(cc1*)ccc1O)=I Chemical compound *CC(CCCCCCN*I)IC(c1c(*)[n]nc1)=*C(c(cc1*)ccc1O)=I 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 2
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 229960000556 fingolimod Drugs 0.000 description 2
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960003433 thalidomide Drugs 0.000 description 2
- QLJYLJGYIDIJPT-VIFPVBQESA-N (2s)-3-(4-aminophenyl)-2-methoxypropanoic acid Chemical compound CO[C@H](C(O)=O)CC1=CC=C(N)C=C1 QLJYLJGYIDIJPT-VIFPVBQESA-N 0.000 description 1
- KSELABKNBIUMGG-YGBAREPYSA-N (2z,3ar,4r,5r,6as)-3,3-difluoro-4-[(e,3r,4r)-3-hydroxy-4-(3-methylphenyl)pent-1-enyl]-2-[4-(2h-tetrazol-5-yl)butylidene]-4,5,6,6a-tetrahydro-3ah-cyclopenta[b]furan-5-ol Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@H]1C1(F)F)/C=C/[C@@H](O)[C@H](C)C=2C=C(C)C=CC=2)\C1=C/CCCC=1N=NNN=1 KSELABKNBIUMGG-YGBAREPYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- MVGWUTBTXDYMND-QGZVFWFLSA-N 2-[(3r)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid Chemical compound C([C@@H]1CC(=O)O)CC(C2=C3)=C1NC2=CC=C3OCC(C=C1C(F)(F)F)=CC=C1C1CCCC1 MVGWUTBTXDYMND-QGZVFWFLSA-N 0.000 description 1
- CAOTVXGYTWCKQE-UHFFFAOYSA-N 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)-1-adamantanecarboxamide Chemical compound C1=CC(Cl)=CC=C1C1(C2)CC(C3)(C(=O)NCC=4C=CN=CC=4)CC2CC3C1 CAOTVXGYTWCKQE-UHFFFAOYSA-N 0.000 description 1
- FWXVGKSWZJEPQI-UHFFFAOYSA-N 3-[[4-[4-[[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]carbamoylamino]naphthalen-1-yl]oxypyrimidin-2-yl]amino]-5-ethynyl-n-[2-[2-(2-methoxyethoxy)ethoxy]ethyl]benzamide Chemical compound C#CC1=CC(C(=O)NCCOCCOCCOC)=CC(NC=2N=C(OC=3C4=CC=CC=C4C(NC(=O)NC=4C(=C(NS(C)(=O)=O)C=C(C=4)C(C)(C)C)OC)=CC=3)C=CN=2)=C1 FWXVGKSWZJEPQI-UHFFFAOYSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XRVDGNKRPOAQTN-FQEVSTJZSA-N 5-[3-[(1s)-1-(2-hydroxyethylamino)-2,3-dihydro-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(C=2C=3CC[C@@H](C=3C=CC=2)NCCO)=NO1 XRVDGNKRPOAQTN-FQEVSTJZSA-N 0.000 description 1
- LYPAFUINURXJSG-AWEZNQCLSA-N 5-benzyl-n-[(3s)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1h-1,2,4-triazole-3-carboxamide Chemical compound N([C@H]1COC2=CC=CC=C2N(C1=O)C)C(=O)C(N=1)=NNC=1CC1=CC=CC=C1 LYPAFUINURXJSG-AWEZNQCLSA-N 0.000 description 1
- MOYPLQILACEGCD-UHFFFAOYSA-N 6-bromo-4-chloro-1h-indazole Chemical compound ClC1=CC(Br)=CC2=C1C=NN2 MOYPLQILACEGCD-UHFFFAOYSA-N 0.000 description 1
- OZOGDCZJYVSUBR-UHFFFAOYSA-N 8-chloro-n-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC1=CC=C(C=CC=C2Cl)C2=N1 OZOGDCZJYVSUBR-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 1
- RZMLYMFSDXUDQZ-UHFFFAOYSA-N BrC1=CC(=C2C=NN(C2=C1)C1OCCCC1)Cl Chemical compound BrC1=CC(=C2C=NN(C2=C1)C1OCCCC1)Cl RZMLYMFSDXUDQZ-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- OJTMTIGSEODYKN-ONEGZZNKSA-N CN(C)C/C=C/C(N1CC(COc2c(cn[nH]3)c3cc(-c(cc3)ccc3O)c2)C1)=O Chemical compound CN(C)C/C=C/C(N1CC(COc2c(cn[nH]3)c3cc(-c(cc3)ccc3O)c2)C1)=O OJTMTIGSEODYKN-ONEGZZNKSA-N 0.000 description 1
- QMTVKOYQNVSGFA-UQKRIMTDSA-N Cl.Oc1ccc(cc1)-c1cc(O[C@H]2CCNC2)c2cn[nH]c2c1 Chemical compound Cl.Oc1ccc(cc1)-c1cc(O[C@H]2CCNC2)c2cn[nH]c2c1 QMTVKOYQNVSGFA-UQKRIMTDSA-N 0.000 description 1
- POWUAPCARCXVQM-UHFFFAOYSA-N ClC1=C2C(=NC(=C1)Cl)N(N=C2)C1OCCCC1 Chemical compound ClC1=C2C(=NC(=C1)Cl)N(N=C2)C1OCCCC1 POWUAPCARCXVQM-UHFFFAOYSA-N 0.000 description 1
- IWHZKBKUHDGXNM-UHFFFAOYSA-N ClC1=CC(=C2C(=N1)N(N=C2)C1OCCCC1)OCC1(CN(C1)C(=O)OC(C)(C)C)CC Chemical compound ClC1=CC(=C2C(=N1)N(N=C2)C1OCCCC1)OCC1(CN(C1)C(=O)OC(C)(C)C)CC IWHZKBKUHDGXNM-UHFFFAOYSA-N 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 239000008961 HMPL-004 Substances 0.000 description 1
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- DNVMTYGOSMEJMV-LBPRGKRZSA-N N1C[C@H](CC1)COC1=C2C=NNC2=CC(=C1)C1=CC=C(C=C1)O Chemical compound N1C[C@H](CC1)COC1=C2C=NNC2=CC(=C1)C1=CC=C(C=C1)O DNVMTYGOSMEJMV-LBPRGKRZSA-N 0.000 description 1
- IMCNLPPDINDJCJ-AWEZNQCLSA-N N1C[C@H](CC1)S(=O)(=O)C1=C2C=NNC2=CC(=C1)C1=CC=C(C=C1)O Chemical compound N1C[C@H](CC1)S(=O)(=O)C1=C2C=NNC2=CC(=C1)C1=CC=C(C=C1)O IMCNLPPDINDJCJ-AWEZNQCLSA-N 0.000 description 1
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 1
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 description 1
- BAGRYRLSWDFIJO-UHFFFAOYSA-N OC(C=C1)=CC=C1C1=CC=C(C=NN2C3OCCCC3)C2=N1 Chemical compound OC(C=C1)=CC=C1C1=CC=C(C=NN2C3OCCCC3)C2=N1 BAGRYRLSWDFIJO-UHFFFAOYSA-N 0.000 description 1
- WJTPLVRNZRJGAS-UHFFFAOYSA-N OC1=CC=C(C=C1)C1=CC(=C2C=NN(C2=C1)C1OCCCC1)OC1(CCN(CC1)C(=O)OC(C)(C)C)C Chemical compound OC1=CC=C(C=C1)C1=CC(=C2C=NN(C2=C1)C1OCCCC1)OC1(CCN(CC1)C(=O)OC(C)(C)C)C WJTPLVRNZRJGAS-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- NCLGDOBQAWBXRA-PGRDOPGGSA-N Telotristat Chemical compound N1=C(C)C=CN1C1=CC(Cl)=CC=C1[C@H](C(F)(F)F)OC1=CC(C=2C=CC(C[C@H](N)C(O)=O)=CC=2)=NC(N)=N1 NCLGDOBQAWBXRA-PGRDOPGGSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- XOYXESIZZFUVRD-UVSAJTFZSA-M acemannan Chemical compound CC(=O)O[C@@H]1[C@H](O)[C@@H](OC)O[C@H](CO)[C@H]1O[C@@H]1[C@@H](O)[C@@H](OC(C)=O)[C@H](O[C@@H]2[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O[C@@H]4[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]5[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]6[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]7[C@H]([C@@H](OC(C)=O)[C@H](OC)[C@@H](CO)O7)O)[C@@H](CO)O6)O)[C@H](O5)C([O-])=O)O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H](CO)O2)O)[C@@H](CO)O1 XOYXESIZZFUVRD-UVSAJTFZSA-M 0.000 description 1
- 229960005327 acemannan Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- KVVMXWRFYAGASO-UHFFFAOYSA-N azetidine-1-carboxylic acid Chemical compound OC(=O)N1CCC1 KVVMXWRFYAGASO-UHFFFAOYSA-N 0.000 description 1
- PBIUUJCEMUAWJJ-UHFFFAOYSA-N azetidine-3-carbonitrile Chemical compound N#CC1CNC1 PBIUUJCEMUAWJJ-UHFFFAOYSA-N 0.000 description 1
- 229960004168 balsalazide Drugs 0.000 description 1
- IPOKCKJONYRRHP-FMQUCBEESA-N balsalazide Chemical compound C1=CC(C(=O)NCCC(=O)O)=CC=C1\N=N\C1=CC=C(O)C(C(O)=O)=C1 IPOKCKJONYRRHP-FMQUCBEESA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229960001684 catridecacog Drugs 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 229940069604 etrasimod Drugs 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 229960004461 interferon beta-1a Drugs 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 230000005980 lung dysfunction Effects 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229950009792 mirikizumab Drugs 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- 229950007074 opaganib Drugs 0.000 description 1
- 229950008141 ozanimod Drugs 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 229950007092 pegilodecakin Drugs 0.000 description 1
- 108091012330 pegilodecakin Proteins 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 1
- 229960003040 rifaximin Drugs 0.000 description 1
- 229950007943 risankizumab Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- OAVGBZOFDPFGPJ-UHFFFAOYSA-N sotrastaurin Chemical compound C1CN(C)CCN1C1=NC(C=2C(NC(=O)C=2C=2C3=CC=CC=C3NC=2)=O)=C(C=CC=C2)C2=N1 OAVGBZOFDPFGPJ-UHFFFAOYSA-N 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229950002246 telotristat Drugs 0.000 description 1
- UZGKJBDWKKBQKC-UHFFFAOYSA-N tert-butyl 3-ethyl-3-(hydroxymethyl)azetidine-1-carboxylate Chemical compound CCC1(CO)CN(C(=O)OC(C)(C)C)C1 UZGKJBDWKKBQKC-UHFFFAOYSA-N 0.000 description 1
- 229940062627 tribasic potassium phosphate Drugs 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229940060746 tulinercept Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021043173A JP2021098751A (ja) | 2017-08-01 | 2021-03-17 | Ｊａｋキナーゼ阻害剤としてのピラゾロおよびトリアゾロ二環式化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539642P | 2017-08-01 | 2017-08-01 | |
| US62/539,642 | 2017-08-01 | ||
| PCT/US2018/044508 WO2019027960A1 (en) | 2017-08-01 | 2018-07-31 | BICYCLIC PYRAZOLO AND TRIAZOLO COMPOUNDS AS JAK KINASE INHIBITORS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021043173A Division JP2021098751A (ja) | 2017-08-01 | 2021-03-17 | Ｊａｋキナーゼ阻害剤としてのピラゾロおよびトリアゾロ二環式化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020529987A JP2020529987A (ja) | 2020-10-15 |
| JP2020529987A5 true JP2020529987A5 (OSRAM) | 2021-04-30 |
| JP7098716B2 JP7098716B2 (ja) | 2022-07-11 |
Family
ID=63209687
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505224A Active JP7098716B2 (ja) | 2017-08-01 | 2018-07-31 | Ｊａｋキナーゼ阻害剤としてのピラゾロおよびトリアゾロ二環式化合物 |
| JP2021043173A Withdrawn JP2021098751A (ja) | 2017-08-01 | 2021-03-17 | Ｊａｋキナーゼ阻害剤としてのピラゾロおよびトリアゾロ二環式化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021043173A Withdrawn JP2021098751A (ja) | 2017-08-01 | 2021-03-17 | Ｊａｋキナーゼ阻害剤としてのピラゾロおよびトリアゾロ二環式化合物 |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10392368B2 (OSRAM) |
| EP (1) | EP3652169A1 (OSRAM) |
| JP (2) | JP7098716B2 (OSRAM) |
| KR (1) | KR20200036004A (OSRAM) |
| CN (1) | CN111032646B (OSRAM) |
| AR (1) | AR112348A1 (OSRAM) |
| AU (1) | AU2018312349A1 (OSRAM) |
| BR (1) | BR112020002265A2 (OSRAM) |
| CA (1) | CA3069990A1 (OSRAM) |
| CL (1) | CL2020000283A1 (OSRAM) |
| CO (1) | CO2020001469A2 (OSRAM) |
| EA (1) | EA038912B1 (OSRAM) |
| IL (1) | IL272031A (OSRAM) |
| MA (1) | MA49570A (OSRAM) |
| MX (1) | MX2020001170A (OSRAM) |
| MY (1) | MY200629A (OSRAM) |
| PE (1) | PE20201028A1 (OSRAM) |
| PH (1) | PH12020500201A1 (OSRAM) |
| SG (1) | SG11202000602YA (OSRAM) |
| TW (1) | TW201920150A (OSRAM) |
| UA (1) | UA125318C2 (OSRAM) |
| WO (1) | WO2019027960A1 (OSRAM) |
| ZA (1) | ZA202000561B (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018312349A1 (en) | 2017-08-01 | 2020-02-06 | Theravance Biopharma R&D Ip, Llc | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors |
| EP3914348A1 (en) | 2019-01-23 | 2021-12-01 | Theravance Biopharma R&D IP, LLC | Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors |
| WO2021009664A1 (en) * | 2019-07-15 | 2021-01-21 | Novartis Ag | Methods for treating meibomian gland dysfunction with liver x receptor agonists |
| WO2021205322A1 (en) * | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof |
| EP4149462A4 (en) | 2020-05-14 | 2024-04-24 | Theravance Biopharma R&D IP, LLC | Administration of gut-selective jak3 inhibitor |
| CN114075221B (zh) * | 2020-08-13 | 2024-08-23 | 广东东阳光药业股份有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| CN114075220A (zh) * | 2020-08-13 | 2022-02-22 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| WO2022053000A1 (zh) * | 2020-09-10 | 2022-03-17 | 四川海思科制药有限公司 | 一种碳环酰胺衍生物及其在医药上的应用 |
| WO2022199599A1 (zh) * | 2021-03-23 | 2022-09-29 | 凯复(苏州)生物医药有限公司 | 丙烯酰基取代的化合物、包含其的药物组合物及其用途 |
| WO2022212181A1 (en) * | 2021-03-29 | 2022-10-06 | Bristol-Myers Squibb Company | Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
| CN113061137B (zh) * | 2021-04-02 | 2022-08-02 | 广西医科大学 | 含氮杂环衍生物或其药学上可接受的盐和用途 |
| FI4333840T3 (fi) * | 2021-05-03 | 2025-12-12 | Incyte Corp | Jak1-reitin estäjiä kyhmykutinan hoitoon |
| CN116332961A (zh) * | 2021-12-23 | 2023-06-27 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| WO2023165562A1 (zh) * | 2022-03-02 | 2023-09-07 | 南京明德新药研发有限公司 | 含氮杂环类化合物及其应用 |
| GB202213163D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| GB202213164D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL366639A1 (en) | 2001-04-20 | 2005-02-07 | Wyeth | Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| FR2836915B1 (fr) | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| PL1638941T3 (pl) | 2003-05-22 | 2010-11-30 | Abbvie Bahamas Ltd | Indazolowe, benzizoksazolowe i benzizotiazolowe inhibitory kinaz |
| EP1647549A1 (en) | 2004-10-14 | 2006-04-19 | Laboratoire Theramex | Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents |
| US20070104780A1 (en) | 2005-10-25 | 2007-05-10 | Lipari John M | Formulation comprising a drug of low water solubility and method of use thereof |
| US20090247554A1 (en) | 2006-03-30 | 2009-10-01 | Takeda San Diego, Inc. | Kinase inhibitors |
| KR100834758B1 (ko) | 2006-07-05 | 2008-06-05 | 삼성전자주식회사 | 컴퓨터 시스템 보안 장치 및 방법 |
| JP2009007342A (ja) | 2007-06-01 | 2009-01-15 | Mitsubishi Tanabe Pharma Corp | 医薬組成物 |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| ATE552255T1 (de) | 2008-06-05 | 2012-04-15 | Glaxo Group Ltd | 4-aminoindazole |
| JP5508400B2 (ja) | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体 |
| JP5502076B2 (ja) | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | 新規化合物 |
| US8653069B2 (en) | 2008-07-28 | 2014-02-18 | Jiangsu Hengyi Pharmaceutical Co., Ltd. | Aralkyl substituted piperidine or piperazine derivatives and their use for treating schizophrenia |
| TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| FR2951172B1 (fr) | 2009-10-13 | 2014-09-26 | Pf Medicament | Derives pyrazolopyridines en tant qu'agent anticancereux |
| EP2507226A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Novel compounds |
| US20120245171A1 (en) | 2009-12-03 | 2012-09-27 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of pi3 kinases |
| TW201200518A (en) | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| HRP20191548T1 (hr) | 2010-11-02 | 2020-02-21 | The Trustees Of Columbia University In The City Of New York | Postupci liječenja poremećaja gubitka kose |
| US8846712B2 (en) | 2011-09-12 | 2014-09-30 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN102993201A (zh) * | 2011-09-14 | 2013-03-27 | 赛诺菲 | 作为激酶抑制剂的6-(4-羟基-苯基)-3-苯乙烯基-1H-吡唑并[3，4-b]吡啶-4-羧酸酰胺衍生物 |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US20130102601A1 (en) | 2011-10-21 | 2013-04-25 | F. Hoffmann-La Roche Ltd | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| EP2771340B1 (en) | 2011-10-25 | 2016-04-13 | Sanofi | 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US8993756B2 (en) * | 2011-12-06 | 2015-03-31 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
| US8377946B1 (en) * | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| EP3459565A1 (en) | 2012-03-29 | 2019-03-27 | The Trustees of Columbia University in the City of New York | Methods for treating hair loss disorders |
| WO2013167403A1 (en) | 2012-05-09 | 2013-11-14 | Sanofi | Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors |
| TWI629275B (zh) | 2013-03-13 | 2018-07-11 | 賽諾菲公司 | Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途 |
| JP2016113366A (ja) * | 2013-03-29 | 2016-06-23 | 大鵬薬品工業株式会社 | アセトアミド基を有する１，２，４−トリアジン−６−カルボキサミド誘導体 |
| ME02883B (me) | 2013-12-05 | 2018-04-20 | Pfizer | PIROLO[2,3-d]PIRIMIDINIL-, PIROLO[2,3-b]PIRAZINIL- I PIROLO[2,3-d] PIRIDINILAKRILAMIDI |
| WO2015112445A1 (en) | 2014-01-24 | 2015-07-30 | Abbvie Inc. | 6-phenyl- or 6-(pyridin-3-yl)indazole derivatives and methods of use |
| AU2015222865B2 (en) * | 2014-02-28 | 2019-06-20 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
| CR20160525A (es) | 2014-05-14 | 2016-12-20 | Pfizer | Pirazolopiridinas y pirazolopirimidinas |
| WO2016011394A1 (en) | 2014-07-18 | 2016-01-21 | The General Hospital Corporation | Imaging agents for neural flux |
| CA2965741C (en) | 2014-11-03 | 2022-05-17 | Iomet Pharma Ltd | Pharmaceutical compound |
| CN105837574B (zh) | 2015-02-02 | 2018-03-02 | 四川大学 | N‑(3‑哌啶基)‑芳香胺衍生物及其制备方法和用途 |
| JP6761815B2 (ja) * | 2015-05-01 | 2020-09-30 | ファイザー・インク | ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、ピロロ［２，３−ｂ］ピリジニルアクリルアミド、およびそのエポキシド |
| MX2017014253A (es) | 2015-05-07 | 2018-04-20 | Univ Columbia | Metodos y composiciones para promover el crecimiento del cabello. |
| US10851097B2 (en) | 2015-11-03 | 2020-12-01 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| WO2017143014A1 (en) | 2016-02-16 | 2017-08-24 | Brian Kim | Jak inhibitors and uses thereof |
| AU2017287762C1 (en) | 2016-06-30 | 2020-04-23 | Daewoong Pharmaceutical Co., Ltd. | Pyrazolopyrimidine derivatives as kinase inhibitor |
| WO2018049174A1 (en) | 2016-09-08 | 2018-03-15 | Synergistic Therapeutics, Llc | Topical hair growth formulation |
| EP3528816A4 (en) | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| US20180117148A1 (en) | 2016-10-28 | 2018-05-03 | Andrew J. Holman | Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders |
| KR102032418B1 (ko) * | 2017-06-15 | 2019-10-16 | 한국화학연구원 | 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| AU2018312349A1 (en) | 2017-08-01 | 2020-02-06 | Theravance Biopharma R&D Ip, Llc | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors |
| CN119119039A (zh) | 2017-11-03 | 2024-12-13 | 阿克拉瑞斯治疗股份有限公司 | 被取代的吡咯并吡啶jak抑制剂及其制造方法和使用方法 |
| KR102577242B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
| KR102577241B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체 |
| ES2922633T3 (es) | 2017-12-28 | 2022-09-19 | Daewoong Pharmaceutical Co Ltd | Derivado de oxi-fluoropiperidina como inhibidor de cinasa |
| EP3914348A1 (en) * | 2019-01-23 | 2021-12-01 | Theravance Biopharma R&D IP, LLC | Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors |
| EP4149462A4 (en) * | 2020-05-14 | 2024-04-24 | Theravance Biopharma R&D IP, LLC | Administration of gut-selective jak3 inhibitor |
-
2018
- 2018-07-31 AU AU2018312349A patent/AU2018312349A1/en not_active Abandoned
- 2018-07-31 BR BR112020002265-9A patent/BR112020002265A2/pt not_active Application Discontinuation
- 2018-07-31 UA UAA202001352A patent/UA125318C2/uk unknown
- 2018-07-31 US US16/050,227 patent/US10392368B2/en active Active
- 2018-07-31 CN CN201880050675.3A patent/CN111032646B/zh not_active Expired - Fee Related
- 2018-07-31 MA MA049570A patent/MA49570A/fr unknown
- 2018-07-31 MY MYPI2020000251A patent/MY200629A/en unknown
- 2018-07-31 SG SG11202000602YA patent/SG11202000602YA/en unknown
- 2018-07-31 KR KR1020207005956A patent/KR20200036004A/ko not_active Withdrawn
- 2018-07-31 PE PE2020000171A patent/PE20201028A1/es unknown
- 2018-07-31 WO PCT/US2018/044508 patent/WO2019027960A1/en not_active Ceased
- 2018-07-31 MX MX2020001170A patent/MX2020001170A/es unknown
- 2018-07-31 EP EP18755621.2A patent/EP3652169A1/en not_active Withdrawn
- 2018-07-31 CA CA3069990A patent/CA3069990A1/en not_active Abandoned
- 2018-07-31 AR ARP180102151 patent/AR112348A1/es unknown
- 2018-07-31 JP JP2020505224A patent/JP7098716B2/ja active Active
- 2018-07-31 TW TW107126579A patent/TW201920150A/zh unknown
- 2018-07-31 EA EA202090413A patent/EA038912B1/ru unknown
-
2019
- 2019-06-28 US US16/456,179 patent/US10538513B2/en active Active
- 2019-11-19 US US16/688,109 patent/US10968205B2/en not_active Expired - Fee Related
-
2020
- 2020-01-14 IL IL272031A patent/IL272031A/en unknown
- 2020-01-27 PH PH12020500201A patent/PH12020500201A1/en unknown
- 2020-01-28 ZA ZA2020/00561A patent/ZA202000561B/en unknown
- 2020-01-31 CL CL2020000283A patent/CL2020000283A1/es unknown
- 2020-02-11 CO CONC2020/0001469A patent/CO2020001469A2/es unknown
-
2021
- 2021-02-22 US US17/249,128 patent/US20220119369A1/en not_active Abandoned
- 2021-03-17 JP JP2021043173A patent/JP2021098751A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020529987A5 (OSRAM) | ||
| JP7053900B2 (ja) | Ｇｌｐ－１受容体アゴニストおよびその使用 | |
| AU2002334205C1 (en) | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | |
| TW444013B (en) | Quinoline and quinazoline compounds useful in treating benign prostatic hyperplasia | |
| EP2864318B1 (en) | 2-aminopyrazine derivatives as csf-1r kinase inhibitors | |
| AU2018392616B2 (en) | Quinazolinones as PARP14 inhibitors | |
| JP6062962B2 (ja) | 置換ピリミジン化合物およびｓｙｋ阻害剤としてのそれらの使用 | |
| EA010487B1 (ru) | Производные тетрагидронафтиридина, пригодные в качестве лигандов рецептора hгистамина | |
| WO2009018909A2 (en) | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | |
| WO2008075172A2 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| TW201240986A (en) | Novel kinase inhibitors | |
| CA2543859A1 (en) | Novel pyridine derivative and pyrimidine derivative (1) | |
| MX2008010899A (es) | Piperidinoilpirrolidinas agonistas del receptor de melanocortina tipo 4. | |
| JPWO2003037862A1 (ja) | アミド誘導体及び医薬 | |
| SG173557A1 (en) | Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof | |
| WO2005033107A1 (en) | Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation | |
| HK1212986A1 (zh) | 作为pde4-抑制剂的苯基乙基吡啶衍生物 | |
| MX2007008757A (es) | Derivados de triazol sustituidos como antagonistas de oxitocina. | |
| JP6574705B2 (ja) | アルドステロン合成酵素（ｃｙｐ１１ｂ２又はｃｙｐ１１ｂ１）阻害剤としての新規ジヒドロキノリン−２−オン誘導体 | |
| JP3269574B2 (ja) | メタノアントラセン化合物、これを含有する神経精神障害を治療するための調剤学的組成物、およびこの化合物を製造するための方法および中間体 | |
| JP2022528919A (ja) | Ｍａｌｔ１阻害剤としての尿素誘導体 | |
| CA3045491A1 (en) | Integrin antagonists | |
| CN111377873B (zh) | 氨基嘧啶化合物及其制备方法和用途 | |
| KR20150068960A (ko) | 치환된 카바메이트 화합물 및 일시적 수용체 전위(trp) 채널 길항제로서의 이의 용도 | |
| JP7734129B2 (ja) | Ｈ－ｐｇｄｓを阻害する縮環化合物 |